Pharsight

Galderma Labs Lp patents expiration

1. Aklief patents expiration

AKLIEF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7807708 GALDERMA LABS LP Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Jul, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 9 months from now)

US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors
Dec, 2025

(1 year, 9 months from now)

US9498465 GALDERMA LABS LP Topical compositions in the form of a gel containing a particular solubilized retinoid
May, 2033

(9 years from now)

US9084778 GALDERMA LABS LP Topical compositions containing a retinoid of the oil-in-water emulsion type
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 4, 2024

Drugs and Companies using TRIFAROTENE ingredient

NCE-1 date: 2023-10-05

Market Authorisation Date: 04 October, 2019

Treatment: Topical treatment of acne vulgaris; Method of activating rargamma receptor; Treatment of acne vulgaris

Dosage: CREAM;TOPICAL

More Information on Dosage

AKLIEF family patents

Family Patents

2. Differin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703820 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Mar, 2023

(11 months ago)

US7834060 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders
Mar, 2023

(11 months ago)

US7868044 GALDERMA LABS LP Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
Mar, 2023

(11 months ago)

US7838558 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Mar, 2023

(11 months ago)

US7737181 GALDERMA LABS LP Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Aug, 2024

(5 months from now)

US7579377 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Feb, 2025

(11 months from now)

US8709392 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
Sep, 2026

(2 years from now)

US8435502 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers
Sep, 2026

(2 years from now)

US7998467 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
May, 2028

(4 years from now)

Drugs and Companies using ADAPALENE ingredient

Market Authorisation Date: 19 June, 2007

Treatment: Treatment of acne; Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage

DIFFERIN family patents

Family Patents

3. Epiduo patents expiration

EPIDUO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8241649 GALDERMA LABS LP Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide
Dec, 2022

(1 year, 2 months ago)

US8936800 GALDERMA LABS LP Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
Dec, 2022

(1 year, 2 months ago)

US8105618 GALDERMA LABS LP Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide
Dec, 2022

(1 year, 2 months ago)

US8809305 GALDERMA LABS LP Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris
Dec, 2022

(1 year, 2 months ago)

US7964202 GALDERMA LABS LP Method for treatment of common acne
Sep, 2024

(6 months from now)

US7820186 GALDERMA LABS LP Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
Nov, 2025

(1 year, 8 months from now)

US8445543 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

US8071644 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

US8080537 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

US8129362 GALDERMA LABS LP Combination/association of adapalene and benzoyl peroxide for treating acne lesions
Jul, 2027

(3 years from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Market Authorisation Date: 08 December, 2008

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage

EPIDUO family patents

Family Patents

4. Epsolay patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868103 GALDERMA LABS LP Metal oxide coating of water insoluble ingredients
Aug, 2028

(4 years from now)

US9687465 GALDERMA LABS LP Compositions for the treatment of rosacea
Nov, 2032

(8 years from now)

US11865100 GALDERMA LABS LP Method for treatment of rosacea in patients aged 65 years and older
Feb, 2040

(15 years from now)

US10933046 GALDERMA LABS LP Method for treatment of rosacea in patients aged 65 years and older
Feb, 2040

(15 years from now)

US10945987 GALDERMA LABS LP Method for providing early onset of action in the treatment of rosacea
Feb, 2040

(15 years from now)

US11541026 GALDERMA LABS LP Method for treatment of rosacea
Feb, 2040

(15 years from now)

US11426378 GALDERMA LABS LP Method for long-term treatment of rosacea
Aug, 2040

(16 years from now)

US11628155 GALDERMA LABS LP Method for therapeutic treatment of rosacea
Dec, 2040

(16 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older; Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

EPSOLAY family patents

Family Patents

5. Metrogel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7348317 GALDERMA LABS LP Aqueous compositions containing metronidazole
Feb, 2022

(2 years ago)

US6881726 GALDERMA LABS LP Aqueous compositions containing metronidazole
Feb, 2022

(2 years ago)

Drugs and Companies using METRONIDAZOLE ingredient

Market Authorisation Date: 30 June, 2005

Treatment: Once a day topical treatment of the inflammatory lesions of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of METROGEL before it's drug patent expiration?
More Information on Dosage

METROGEL family patents

Family Patents

6. Mirvaso patents expiration

MIRVASO's oppositions filed in EPO
MIRVASO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2024

(2 months from now)

US8231885 GALDERMA LABS LP Compounds, formulations, and methods for ameliorating telangiectasis
May, 2025

(1 year, 2 months from now)

US8426410 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2025

(1 year, 2 months from now)

US8410102 GALDERMA LABS LP Methods and compositions for treating or preventing erythema
May, 2025

(1 year, 2 months from now)

US7439241 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing rosacea
Aug, 2025

(1 year, 5 months from now)

US8513249 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(7 years from now)

US9861631 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(7 years from now)

US9861632 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(7 years from now)

US8513247 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(7 years from now)

US8163725 GALDERMA LABS LP Gel compositions and methods of use
Jun, 2031

(7 years from now)

US10201517 GALDERMA LABS LP Brimonidine gel compositions and methods of use
Jun, 2031

(7 years from now)

US8053427 GALDERMA LABS LP Brimonidine gel composition
Jun, 2031

(7 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of MIRVASO before it's drug patent expiration?
More Information on Dosage

MIRVASO family patents

Family Patents

7. Oracea patents expiration

ORACEA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7211267 GALDERMA LABS LP Methods of treating acne
Apr, 2022

(1 year, 10 months ago)

US9241946 GALDERMA LABS LP Methods of treating acne
Apr, 2022

(1 year, 10 months ago)

US10058564 GALDERMA LABS LP Methods of treating acne
Apr, 2022

(1 year, 10 months ago)

US8603506 GALDERMA LABS LP Methods of treating acne
Apr, 2022

(1 year, 10 months ago)

US7232572 GALDERMA LABS LP Methods of treating rosacea
Apr, 2022

(1 year, 10 months ago)

US8470364 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(a month from now)

US8394406 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(a month from now)

US8709478 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(a month from now)

US8394405 GALDERMA LABS LP Once daily formulations of tetracyclines
Apr, 2024

(a month from now)

US8206740 GALDERMA LABS LP Once daily formulations of tetracyclines
Dec, 2025

(1 year, 9 months from now)

US7749532 GALDERMA LABS LP Once daily formulations of tetracyclines
Dec, 2027

(3 years from now)

Drugs and Companies using DOXYCYCLINE ingredient

Market Authorisation Date: 26 May, 2006

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

How can I launch a generic of ORACEA before it's drug patent expiration?
More Information on Dosage

ORACEA family patents

Family Patents

8. Soolantra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8093219 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month from now)

US8415311 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month from now)

US8815816 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month from now)

US7550440 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month from now)

US8470788 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month from now)

US8080530 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month from now)

US11033565 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions
Apr, 2024

(a month from now)

US9233117 GALDERMA LABS LP Treatment of inflammatory lesions of rosacea with ivermectin
Mar, 2034

(10 years from now)

US9782425 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(10 years from now)

US10206939 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(10 years from now)

US9089587 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(10 years from now)

US9233118 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin
Mar, 2034

(10 years from now)

Drugs and Companies using IVERMECTIN ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

How can I launch a generic of SOOLANTRA before it's drug patent expiration?
More Information on Dosage

SOOLANTRA family patents

Family Patents

9. Tri-luma patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8653053 GALDERMA LABS LP Topical skin care composition
Oct, 2022

(1 year, 4 months ago)

US8247395 GALDERMA LABS LP Topical skin care composition
Oct, 2022

(1 year, 4 months ago)

US7915243 GALDERMA LABS LP Topical skin care composition
Sep, 2023

(5 months ago)

US7939516 GALDERMA LABS LP Topical skin care composition
Sep, 2023

(5 months ago)

Drugs and Companies using FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN ingredient

Market Authorisation Date: 18 January, 2002

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

TRI-LUMA family patents

Family Patents

10. Twyneo patents expiration

Can you believe TWYNEO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617580 GALDERMA LABS LP Compositions for topical application comprising a peroxide and retinoid
Feb, 2028

(3 years from now)

US9868103 GALDERMA LABS LP Metal oxide coating of water insoluble ingredients
Aug, 2028

(4 years from now)

US10653899 GALDERMA LABS LP Core stabilized microcapsules, method of their preparation and uses thereof
Dec, 2030

(6 years from now)

US11071878 GALDERMA LABS LP Core stabilized microcapsules, method of their preparation and uses thereof
Dec, 2030

(6 years from now)

US10420743 GALDERMA LABS LP Methods and compositions for the treatment of acne
Jul, 2038

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination (NC) Jul 26, 2024

Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient

Market Authorisation Date: 26 July, 2021

Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

TWYNEO family patents

Family Patents